Blend CJC-1295 + Ipamorelin + GHRP-2 (9mg): The Triple GHRH/GHRP Synergistic Growth Hormone-Releasing Peptide Combination — Combining the Long-Acting GHRH Analog CJC-1295 with Two Complementary GHRPs (Ipamorelin for Selectivity + GHRP-2 for Potency) for Maximum Pulsatile Growth Hormone Release, IGF-1 Elevation, and Balanced Side Effect Profile
The CJC-1295 + Ipamorelin + GHRP-2 blend (9mg total per vial) is a triple-peptide growth hormone-releasing combination that brings together the long-acting GHRH analog CJC-1295 (modified GRF 1-29) with two complementary GHRPs: Ipamorelin (the most selective, gentlest GHRP with minimal prolactin/ACTH/appetite effects) and GHRP-2 (a potent, more GH-selective GHRP with minimal appetite stimulation but moderate prolactin/ACTH effects). This 9mg blend vial typically contains a ratio of the three peptides (commonly ~3mg CJC-1295 + ~3mg Ipamorelin + ~3mg GHRP-2, or other proportions — users should verify the exact ratio from their supplier's Certificate of Analysis). The triple combination is designed to leverage the complementary strengths of each peptide: CJC-1295 provides the sustained GHRH signal and somatotroph priming (GH synthesis), Ipamorelin provides selective, gentle GH release with minimal off-target effects, and GHRP-2 provides potent, reliable GH release with a slightly different pharmacological profile. Together, the two GHRPs (Ipamorelin + GHRP-2) may produce more robust and consistent GH release than either GHRP alone, while CJC-1295 provides the GHRH component for the classic GHRH/GHRP synergy. The blend works through the classic GHRH/GHRP synergy amplified by two GHRPs: CJC-1295 (GHRH analog) stimulates GH synthesis via the cAMP/PKA pathway and primes the pituitary somatotroph; both Ipamorelin and GHRP-2 (GHSR-1a agonists) stimulate acute GH release via the PLC/IP3/calcium pathway and inhibit somatostatin at the hypothalamic level. The two GHRPs may have additive or synergistic effects at the GHSR-1a receptor (though they bind the same receptor, their different binding kinetics and conformational effects may produce more sustained or robust receptor activation). Together, they produce powerful pulsatile growth hormone release with a balanced side effect profile (Ipamorelin's selectivity helps offset GHRP-2's moderate prolactin/ACTH effects). The research-grade CJC-1295 + Ipamorelin + GHRP-2 blend supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use[1][2][3][4][5][6][7][8][9][10].
Comparative Analysis: The Three Peptides in This Blend
Those wanting potent GH release, general use, cutting (minimal appetite)
As shown in the comparative table above, each of the three peptides in this blend plays a distinct and complementary role. CJC-1295 provides the essential GHRH component — it stimulates GH synthesis (gene transcription) via the cAMP/PKA/CREB pathway, primes the somatotroph for GH release, and has a long half-life (~6-12 days) that provides a sustained GHRH "background" signal. However, CJC-1295 alone is limited because its GH-releasing effect is strongly suppressed by somatostatin (the primary inhibitor of GH secretion). Ipamorelin is the most selective GHRP — it has high GH-releasing potency (similar to GHRP-2) but with minimal effects on prolactin, ACTH/cortisol, and appetite. Its unique amino acid substitutions (Aib, D-2-Nal, D-Phe) give it a selective receptor binding profile that favors GH release over other GHSR-mediated effects. Ipamorelin also has a longer half-life (~90-120 min) than GHRP-2 (~30-60 min) due to the Aib substitution, providing more sustained GH-releasing activity per dose. GHRP-2 is a potent and reliable GHRP — it produces robust acute GH pulses via the PLC/IP3/calcium pathway, with minimal appetite stimulation (unlike GHRP-6) but moderate prolactin/ACTH effects (more than Ipamorelin). GHRP-2's shorter half-life (~30-60 min) produces sharp, discrete GH pulses. The combination of Ipamorelin (longer half-life, selective, gentle) + GHRP-2 (shorter half-life, potent, reliable) may produce more robust and sustained GHSR-1a receptor activation than either GHRP alone — the two peptides may have additive effects due to their different binding kinetics and conformational effects on the receptor (though they bind the same receptor, their different structures may produce slightly different receptor conformations and signaling biases). Together with CJC-1295 (GHRH component), the triple blend produces powerful synergistic GH release: CJC-1295 primes the somatotroph (GH synthesis), while the two GHRPs trigger massive GH exocytosis (calcium release) and inhibit somatostatin at the hypothalamus. The side effect profile is balanced — Ipamorelin's minimal prolactin/ACTH/appetite effects help offset GHRP-2's moderate effects on these hormones, making the triple blend potentially better tolerated than a CJC-1295 + GHRP-2 blend alone, while still providing the potent GH release of GHRP-2[1][2][3][4][5][6][7][8][9][10].
Why Combine Two GHRPs (Ipamorelin + GHRP-2)?
The combination of two GHRPs (Ipamorelin + GHRP-2) in this blend is a distinctive feature that deserves explanation, since most GHRH/GHRP combinations use only one GHRP. The rationale for combining two GHRPs includes: (a) Additive or synergistic GHSR-1a receptor activation: Although Ipamorelin and GHRP-2 both bind to the GHSR-1a (ghrelin) receptor, they have different chemical structures, binding kinetics, and conformational effects on the receptor. Ipamorelin (pentapeptide with Aib and D-2-Nal substitutions) may bind with slightly different affinity and induce a slightly different receptor conformation than GHRP-2 (hexapeptide with D-Ala and D-β-Nal substitutions). This could lead to biased signaling (different downstream signaling pathway activation) or more sustained receptor activation (the two peptides may have different dissociation rates, providing more continuous receptor stimulation). Some researchers and clinicians believe that combining two GHRPs with different pharmacokinetic profiles can produce more robust and consistent GH release than either GHRP alone — the longer-acting Ipamorelin (~90-120 min half-life) provides sustained receptor activation, while the shorter-acting GHRP-2 (~30-60 min half-life) produces a sharp initial pulse; (b) Balanced side effect profile: GHRP-2 is a potent GH secretagogue but has moderate effects on prolactin and ACTH/cortisol. Ipamorelin is the most selective GHRP with minimal prolactin/ACTH/appetite effects. By combining the two, the blend may achieve the potent GH release of GHRP-2 while the Ipamorelin component helps "dilute" or balance the off-target effects of GHRP-2 (since a portion of the total GHRP dose comes from the more selective Ipamorelin, the effective dose of GHRP-2 is lower than it would be in a CJC+GHRP-2-only blend with the same total GHRP content). This could result in a better tolerated blend with fewer prolactin/cortisol-related side effects than a CJC+GHRP-2 blend of equivalent total GHRP dose; (c) Complementary pharmacokinetics: Ipamorelin has a longer half-life (~90-120 min) than GHRP-2 (~30-60 min). The combination may provide both an initial sharp GH pulse (from GHRP-2's rapid onset and short half-life) and a more sustained GH-releasing effect (from Ipamorelin's longer half-life), potentially producing a broader and more robust GH release profile than either GHRP alone. This could be advantageous for maximizing total GH output per dose; (d) Reduced receptor desensitization: Continuous or high-dose stimulation of GHSR-1a can lead to receptor desensitization and downregulation (reduced responsiveness over time). Using two GHRPs with different binding profiles may potentially reduce the rate or extent of receptor desensitization compared to using a single GHRP at high doses, though this is theoretical and requires more research; (e) Individual variability: Different individuals may respond differently to different GHRPs due to genetic variations in GHSR-1a receptor expression, receptor polymorphisms, metabolic differences, and other factors. Combining two GHRPs increases the likelihood that at least one will be highly effective for a given individual, and may produce more consistent results across a population. It is important to note that the combination of two GHRPs is still an area of active research, and the optimal ratio, dosing, and long-term safety of dual-GHRP combinations are not yet fully established. The triple blend (CJC-1295 + Ipamorelin + GHRP-2) is a research-grade product intended for laboratory and investigational use only, and users should verify the exact peptide ratio from the supplier's COA and monitor IGF-1 and side effects carefully[2][3][4][7][9][10].
Mechanism of Action: The Triple GHRH/GHRP Synergy
The mechanism of action of the CJC-1295 + Ipamorelin + GHRP-2 blend involves the classic GHRH/GHRP synergy, amplified by the use of two complementary GHRPs: (a) CJC-1295 (GHRH Analog) — The Sustained GHRH Signal and GH Synthesis Priming: CJC-1295 binds to GHRH receptors (GHRHR, Gs-GPCR) on pituitary somatotrophs, activating the adenylyl cyclase → cAMP → PKA → CREB pathway, which stimulates growth hormone gene transcription and GH synthesis (building up GH stores in the somatotroph). PKA also phosphorylates and activates L-type voltage-gated calcium channels, sensitizing the somatotroph to calcium-mediated GH release. CJC-1295's long half-life (~6-12 days) provides a sustained GHRH "background" signal that keeps the somatotroph primed. However, CJC-1295 alone is limited because somatostatin (GHIH) suppresses its effects by inhibiting cAMP production and calcium influx; (b) Ipamorelin (Selective GHSR-1a Agonist) — The Selective, Sustained GH Release Trigger: Ipamorelin binds to GHSR-1a (ghrelin receptor, Gq/11-GPCR) on pituitary somatotrophs and hypothalamic neurons, activating the PLC → PIP2 → IP3 + DAG pathway. IP3 binds to IP3 receptors on the endoplasmic reticulum, causing intracellular calcium release that triggers GH exocytosis. DAG activates PKC, further enhancing GH release. At the hypothalamus, Ipamorelin stimulates GHRH release and inhibits somatostatin release (removing the "brake" on GH). Ipamorelin's unique structure gives it high GH selectivity (minimal prolactin/ACTH/appetite effects) and a longer half-life (~90-120 min), providing sustained GH-releasing activity; (c) GHRP-2 (Potent GHSR-1a Agonist) — The Potent, Acute GH Release Trigger: GHRP-2 also binds to GHSR-1a on pituitary somatotrophs and hypothalamic neurons, activating the same PLC/IP3/DAG/calcium pathway. GHRP-2 produces potent, reliable acute GH pulses with a shorter half-life (~30-60 min), resulting in sharp, discrete GH release. At the hypothalamus, GHRP-2 also stimulates GHRH release and inhibits somatostatin. GHRP-2 has moderate prolactin/ACTH effects (more than Ipamorelin, less than GHRP-6) and minimal appetite stimulation; (d) The Triple Synergy: The combination of CJC-1295 + Ipamorelin + GHRP-2 produces synergistic GH release through multiple converging mechanisms: (i) Pituitary-level synergy: CJC-1295 (Gs/cAMP/PKA pathway) primes the somatotroph by increasing GH synthesis and sensitizing calcium channels, while both Ipamorelin and GHRP-2 (Gq/PLC/IP3/calcium pathway) trigger massive GH exocytosis. The two GHRPs may have additive effects on GHSR-1a activation due to their different binding kinetics and conformational effects; (ii) Hypothalamic-level synergy: Both GHRPs stimulate hypothalamic GHRH release (complementing exogenous CJC-1295) and inhibit somatostatin release (removing the brake that limits CJC-1295's effectiveness); (iii) Complementary pharmacokinetics: Long-acting CJC-1295 (sustained GHRH background) + medium-acting Ipamorelin (~90-120 min, sustained GH release) + short-acting GHRP-2 (~30-60 min, acute GH pulse) = a multi-phase GH release profile that may produce more total GH output than any single or dual combination; (iv) Balanced side effects: Ipamorelin's minimal prolactin/ACTH/appetite effects help balance GHRP-2's moderate effects on these hormones; (v) IGF-1 elevation: The greater GH release translates to greater hepatic IGF-1 production (30-100%+ elevation), which is the primary downstream mediator of GH's effects and the primary biomarker for monitoring. The triple blend therefore represents a "maximalist" approach to GHRH/GHRP synergy, combining the essential GHRH component with two complementary GHRPs for robust, sustained GH release with a balanced side effect profile[1][2][3][4][5][6][7][8][9][10].
Key Research Applications for the Triple Blend
1. Maximum Growth Hormone Release and IGF-1 Elevation — For Those Who Want Robust GH Output: The CJC-1295 + Ipamorelin + GHRP-2 triple blend is designed for individuals who want maximum, robust growth hormone release and IGF-1 elevation, while still maintaining a reasonable side effect profile. The combination of the GHRH analog (CJC-1295) with two complementary GHRPs (Ipamorelin + GHRP-2) may produce more total GH output than a single-GHRP combination (like CJC+GHRP-2 or CJC+Ipamorelin) due to: (a) additive GHSR-1a receptor activation from two GHRPs with different binding profiles; (b) complementary pharmacokinetics (long-acting CJC + medium-acting Ipamorelin + short-acting GHRP-2 = multi-phase GH release); (c) more robust somatostatin inhibition (both GHRPs inhibit somatostatin at the hypothalamus, potentially producing greater net somatostatin suppression than one GHRP alone); (d) greater hypothalamic GHRH stimulation (both GHRPs stimulate GHRH release, complementing exogenous CJC-1295). The expected result is powerful pulsatile GH release and significant IGF-1 elevation (30-100%+ depending on dose, duration, and individual response). IGF-1 is the primary biomarker for monitoring — serum IGF-1 should be measured after 4-6 weeks of dosing, and the dose should be adjusted to keep IGF-1 in the upper-normal physiological range for age (~200-350 ng/mL adults), NOT supraphysiological. The triple blend is particularly suitable for: (i) individuals who have tried single-GHRP combinations and want more robust GH release; (ii) individuals with lower GH responsiveness (who may need stronger stimulation to achieve meaningful IGF-1 elevation); (iii) individuals who want to maximize the anabolic/lipolytic/recovery benefits of GH/IGF-1 while maintaining a balanced side effect profile (Ipamorelin helps offset GHRP-2's off-target effects). It is important to note that "more is not always better" — supraphysiological GH/IGF-1 levels can increase the risk of side effects (insulin resistance, edema, carpal tunnel, acromegaly-like features with long-term use, and theoretical cancer risk), so careful IGF-1 monitoring and dose titration are essential. The goal is physiological optimization (upper-normal IGF-1), not supraphysiological levels[1][2][3][5][6][8][10].
2. Body Composition, Muscle Growth, and Fat Loss — The "Power" Recomposition Blend: Like other GHRH/GHRP combinations, the triple blend is researched for its effects on body composition — increasing lean muscle mass and reducing body fat — with the advantage of potentially more robust GH/IGF-1 elevation than single-GHRP combinations. The anabolic (muscle-building) and lipolytic (fat-burning) effects are mediated through both GH and IGF-1: (a) Muscle growth (anabolic effects): GH and IGF-1 stimulate muscle protein synthesis (via mTOR pathway activation, satellite cell activation, amino acid uptake) and inhibit muscle protein breakdown (via inhibition of the ubiquitin-proteasome pathway and myostatin reduction), leading to net protein accretion and muscle hypertrophy. Studies of GH replacement show 5-10% increases in lean body mass over 6-12 months, and GHRH/GHRP combinations produce similar (though often more modest) effects. When combined with resistance training and adequate protein intake (1.6-2.2g/kg/day), the anabolic effects are significantly enhanced. The triple blend's potentially more robust GH/IGF-1 elevation may produce greater anabolic effects than single-GHRP combinations, though this needs to be balanced against the risk of supraphysiological levels; (b) Fat loss (lipolytic effects): GH is a potent lipolytic hormone — it stimulates triglyceride breakdown in adipose tissue (via hormone-sensitive lipase activation) and inhibits lipoprotein lipase (which promotes fat storage). GH particularly targets visceral/abdominal fat (the metabolically dangerous fat around internal organs), which is more sensitive to GH's lipolytic effects. IGF-1 also contributes to fat loss indirectly by improving insulin sensitivity (at physiological levels) and promoting nutrient partitioning. Studies of GH replacement show 10-15% reductions in fat mass over 6-12 months, with the greatest reductions in visceral fat. GHRH/GHRP peptides have shown similar fat loss effects, particularly when combined with calorie restriction and exercise. The triple blend's minimal appetite stimulation (both Ipamorelin and GHRP-2 have minimal appetite effects, unlike GHRP-6) makes it suitable for fat loss phases where maintaining a caloric deficit is important — unlike GHRP-6-based blends which can increase hunger and make dieting harder; (c) Body recomposition: The combination of muscle gain and fat loss produces an overall improvement in body composition (higher lean mass percentage, lower fat mass percentage), even if body weight does not change dramatically. The triple blend is often preferred for body composition goals by individuals who want more robust GH/IGF-1 elevation than single-GHRP combinations can provide, while still maintaining minimal appetite stimulation (suitable for both cutting and "clean bulking") and a balanced side effect profile (Ipamorelin helps offset GHRP-2's prolactin/ACTH effects). The use of GH-releasing peptides for athletic performance enhancement is prohibited by WADA and most sports governing bodies (doping), and the research-grade blend is intended for laboratory/investigational use only[1][2][3][5][6][8][10].
3. Recovery, Tissue Repair, and Connective Tissue Healing: The triple blend is researched for its effects on post-workout recovery, tissue repair, and connective tissue (tendon/ligament/cartilage/bone) healing, mediated through GH/IGF-1. The potentially more robust GH/IGF-1 elevation of the triple blend may produce enhanced recovery and tissue repair effects compared to single-GHRP combinations: (a) Post-workout recovery: GH/IGF-1 enhance recovery from intense exercise by stimulating muscle protein synthesis (repairing microtrauma), reducing muscle protein breakdown, promoting connective tissue repair, improving sleep quality (essential for recovery), and reducing exercise-induced muscle damage markers (creatine kinase, myoglobin). Many users report reduced DOMS (delayed onset muscle soreness) and faster recovery between training sessions; (b) Tendon and ligament healing: Tendons/ligaments have poor blood supply and slow healing. GH/IGF-1 promote tendon/ligament healing by stimulating collagen synthesis (type I collagen), fibroblast proliferation/migration, angiogenesis (improving blood supply), and improving the organization and mechanical strength of repaired tissue. Preclinical studies show accelerated tendon healing with GH/IGF-1. GHRH/GHRP peptides are used anecdotally for tendon injuries (Achilles tendinopathy, rotator cuff, tennis elbow, jumper's knee, plantar fasciitis) and ligament sprains, often in combination with other healing peptides (BPC-157, TB-500); (c) Cartilage and joint health: GH/IGF-1 may support cartilage health by stimulating chondrocyte proliferation and matrix synthesis (type II collagen, aggrecan), reducing cartilage degradation (MMP inhibition), and improving joint lubrication. While they cannot fully regenerate damaged articular cartilage, they may help slow degeneration and support cartilage health in early osteoarthritis; (d) Bone healing and density: GH/IGF-1 are essential for bone growth and remodeling — they promote osteoblast proliferation/activity, bone matrix synthesis, calcium/phosphate metabolism, angiogenesis at fracture sites, and fracture callus formation. GH deficiency is associated with reduced bone density, and GH replacement increases bone mineral density (over 12-24 months). GHRH/GHRP peptides may support bone health and fracture healing; (e) Skin and wound healing: GH/IGF-1 promote skin health and wound healing by stimulating collagen/elastin synthesis, keratinocyte proliferation/migration (re-epithelialization), dermal thickness, skin elasticity/hydration, and accelerated wound closure. GH deficiency is associated with thin, dry skin and impaired wound healing, and GH replacement improves these; (f) Organ repair and protection: GH/IGF-1 have protective and regenerative effects on various organs — liver (hepatocyte regeneration, anti-fibrotic), kidney (renoprotective), heart (cardioprotective, improved cardiac function), and nervous system (neuroprotective, neurogenesis). The triple blend may therefore support overall tissue repair and regeneration, with potentially enhanced effects due to more robust GH/IGF-1 elevation[1][2][3][5][6][8][10].
4. Sleep, Cognition, Mood, and Quality of Life — With Balanced Hormonal Effects: The triple blend is researched for its effects on sleep, cognition, mood, and quality of life — domains that are often affected by GH deficiency and aging, and where the balanced hormonal profile of the triple blend (Ipamorelin's minimal prolactin/ACTH effects helping offset GHRP-2's moderate effects) may be advantageous: (a) Sleep quality: GH is primarily released during deep slow-wave sleep (stages 3-4 NREM), and there is a bidirectional relationship between GH and sleep. GH deficiency is associated with poor sleep quality, reduced slow-wave sleep, frequent nighttime awakenings, and daytime fatigue. GH replacement and GH-releasing peptides have been reported to improve sleep quality: deeper, more restorative sleep, fewer nighttime awakenings, better sleep architecture (more slow-wave sleep), and reduced daytime fatigue. Many users report improved sleep as one of the first noticeable effects (within 1-2 weeks). The triple blend's minimal appetite stimulation (both Ipamorelin and GHRP-2 have minimal appetite effects, unlike GHRP-6) means it is less likely to cause nighttime hunger if dosed before bed, making bedtime dosing well-tolerated; (b) Cognitive function: GH receptors (GHR) and IGF-1 receptors (IGF-1R) are widely expressed in the brain (hippocampus, cerebral cortex, hypothalamus). GH/IGF-1 support neurogenesis (particularly in the hippocampal dentate gyrus — important for memory/learning), synaptic plasticity (the cellular basis of learning/memory), neuronal survival/protection (anti-apoptotic, antioxidant, anti-inflammatory), cerebral blood flow, and neurotransmitter regulation (dopamine, serotonin, glutamate, GABA). GH deficiency is associated with cognitive impairment and increased dementia risk, and GH replacement may improve cognitive function. GHRH/GHRP peptides may support cognitive function by increasing GH/IGF-1, particularly in those with age-related GH decline. The triple blend's balanced ACTH/cortisol effects (Ipamorelin's minimal cortisol effect helping offset GHRP-2's moderate effect) are advantageous for cognition because elevated cortisol can impair cognition and memory (particularly hippocampal function); (c) Mood and psychological well-being: GH deficiency is strongly associated with reduced quality of life, depression, anxiety, irritability, and social isolation. These psychological symptoms can improve significantly with GH replacement. Mechanisms include: neurotransmitter modulation (dopamine — reward/motivation; serotonin — mood/anxiety; GABA — anxiety reduction), hippocampal neurogenesis (reduced neurogenesis is linked to depression/anxiety), anti-inflammatory effects (chronic inflammation is linked to depression), improved body composition/physical function (improved self-esteem), and improved sleep (poor sleep is linked to mood disorders). Many users report improved mood, motivation, and well-being with GHRH/GHRP peptides. The triple blend's balanced prolactin effects (Ipamorelin's minimal prolactin effect helping offset GHRP-2's moderate effect) are advantageous for mood because elevated prolactin can cause mood changes and sexual dysfunction; (d) Energy and vitality: GH deficiency is characterized by fatigue, low energy, reduced exercise capacity, and reduced vitality. GH replacement and GH-releasing peptides often improve energy levels, exercise capacity, and vitality through: improved muscle mass/strength, reduced fat mass, improved cardiac function/exercise capacity, better sleep, improved mood/motivation, and enhanced mitochondrial function. Many users report increased energy and vitality as a key benefit; (e) Long-term tolerability: The triple blend's balanced side effect profile (Ipamorelin's selectivity helping offset GHRP-2's off-target effects) may make it more tolerable for long-term use than a CJC+GHRP-2-only blend, while still providing the potent GH release of GHRP-2. Regular monitoring (IGF-1, glucose, lipids, liver/kidney function, CBC, prolactin, cortisol, PSA in men, body composition, symptoms) is essential for long-term use[1][2][3][5][6][8][10].
5. Research into Dual GHRP Combinations and GHSR-1a Pharmacology: Beyond the direct applications of GH/IGF-1 elevation, the CJC-1295 + Ipamorelin + GHRP-2 triple blend (and particularly the dual-GHRP component) is a valuable research tool for studying: (a) Dual GHRP combinations: The combination of two GHRPs (Ipamorelin + GHRP-2) is an active area of research, with questions about optimal ratios, dosing, pharmacokinetics, receptor binding interactions, signaling bias, desensitization, and long-term safety. The triple blend provides a pre-formulated combination for studying these questions; (b) GHSR-1a (ghrelin receptor) pharmacology: Ipamorelin and GHRP-2 are both GHSR-1a agonists but with different structures, binding kinetics, and conformational effects. Studying their combination can provide insights into GHSR-1a receptor structure-function relationships, ligand-receptor interactions, biased agonism, receptor desensitization/internalization, and tissue-specific signaling; (c) GH secretion physiology: The triple blend is a tool for studying the physiology of pulsatile GH secretion, the GHRH/somatostatin/GHRP regulatory axis, pituitary somatotroph function, and the mechanisms of GHRH-GHRP synergy — particularly the effects of dual GHRP stimulation on GH release patterns; (d) Structure-activity relationship (SAR) research: Comparing the effects of Ipamorelin (pentapeptide with Aib/D-2-Nal) and GHRP-2 (hexapeptide with D-Ala/D-β-Nal) and their combination can inform SAR studies of GH secretagogues, helping to identify the structural features that confer GH selectivity, potency, metabolic stability, and side effect profiles; (e) Clinical research applications: The triple blend may be researched for clinical applications including GH deficiency diagnosis (GH stimulation testing), GH deficiency treatment (as a potential alternative to exogenous GH with more physiological pulsatile release), and catabolic/wasting conditions (though GHRP-6 may be more suitable for wasting due to its appetite stimulation). The triple blend is therefore a versatile research tool for studying multiple aspects of GH/IGF-1 physiology and GHSR pharmacology[1][2][3][4][7][9][10].
References
Bowers CY. Growth hormone-releasing peptide (GHRP) and its relationship to growth hormone-releasing hormone (GHRH) and somatostatin. Endocrinology and Metabolism Clinics of North America. 1998;27(2):353-368. (Comprehensive review by the discoverer of GHRPs, covering: GHRP family (GHRP-1, GHRP-2, GHRP-6, hexarelin, ipamorelin), GHSR-1a receptor (ghrelin receptor), mechanism of action (PLC/IP3/DAG/calcium), hypothalamic effects (GHRH stimulation + somatostatin inhibition), the GHRH + GHRP synergy (pituitary and hypothalamic levels), pulsatile GH release, GHRP selectivity (ipamorelin as the most selective), dual GHRP combinations, and clinical applications; foundational reference for GHRPs including ipamorelin and GHRP-2 and the GHRH/GHRP combination; relevant to the triple blend)
Clark RG, Robinson ICAF. The growth hormone-releasing peptide (GHRP) and growth hormone-releasing hormone (GHRH) interaction: a review. Journal of Endocrinology. 1996;149(3):387-394. (Review of the GHRH + GHRP synergy, covering: pituitary-level synergy (cAMP/PKA + IP3/calcium pathways converging on somatotroph), hypothalamic-level synergy (GHRP stimulates GHRH release + inhibits somatostatin), dose-response relationships, pulsatile GH release patterns, in vitro and in vivo data showing 2-10x greater GH release with combination vs either alone, and clinical implications; directly relevant to the triple blend's mechanism of synergy, including the potential for additive effects with dual GHRPs)
Pihoker C, Kearns GL, French D, et al. Growth hormone-releasing peptide-2 (GHRP-2, KP-102): pharmacokinetics and pharmacodynamics in children. Journal of Clinical Endocrinology & Metabolism. 1998;83(10):3627-3632. (Clinical study of GHRP-2 in children, covering: pharmacokinetics (half-life ~30-60 min), pharmacodynamics (dose-dependent GH release), safety/tolerability, comparison with GHRH, GHRP-6, and ipamorelin, the synergistic effect when combined with GHRH, and effects on prolactin/ACTH/cortisol; provides clinical data on GHRP-2 specifically, including its moderate prolactin/ACTH effects and minimal appetite stimulation; relevant to understanding GHRP-2's role in the triple blend and its comparison with Ipamorelin)
Raun K, Johansen JL, Ribel U, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. (LANDMARK paper introducing ipamorelin as the first selective growth hormone secretagogue; covering: ipamorelin's structure (Aib-His-D-2-Nal-D-Phe-Lys-NH2), development through structure-activity relationship (SAR) studies, GH-releasing potency (comparable to GHRP-6/GHRP-2), MINIMAL effects on prolactin, ACTH/cortisol, and appetite (unlike GHRP-6/GHRP-2), pharmacokinetics (half-life ~90-120 min, longer than GHRP-6/GHRP-2 due to Aib substitution), safety/tolerability, and the significance of ipamorelin as the most selective GHRP; foundational reference for ipamorelin and its unique selectivity profile; directly relevant to the triple blend and why ipamorelin is included to balance GHRP-2's off-target effects)
Brooks AJ, Levinson N, Waters MJ. New insights into growth hormone action. Journal of Molecular Endocrinology. 2008;41(1):1-8. (Review of GH signaling and actions, covering: GH receptor (GHR) structure and activation, JAK2/STAT5 signaling pathway, MAPK and PI3K/Akt pathways, GH effects on gene transcription (IGF-1, SOCS, etc.), direct vs indirect (IGF-1-mediated) effects, tissue-specific actions (muscle, fat, bone, liver, brain), GH and metabolism (anabolic, lipolytic, anti-insulin), and GH and aging (somatopause); provides the mechanistic foundation for understanding how increased GH/IGF-1 from the triple blend produces its effects; relevant to downstream effects of GH/IGF-1 elevation)
Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nature Reviews Endocrinology. 2013;9(6):366-376. (Comprehensive review of the GH/IGF-1 axis in aging and longevity, covering: somatopause (age-related GH/IGF-1 decline — 14% per decade after age 30), effects of GH deficiency on aging (sarcopenia, osteopenia, skin atrophy, reduced energy, cognitive decline, increased cardiovascular risk), GH replacement therapy benefits and risks, the paradox of reduced GH/IGF-1 signaling and increased lifespan in model organisms (GHRKO mice, Ames dwarf, IGF-1R mutations), human centenarian studies, the U-shaped/inverted-U relationship between GH/IGF-1 and longevity, and the role of GH/IGF-1 in age-related diseases (cancer, diabetes, cardiovascular disease, neurodegeneration); directly relevant to the anti-aging/longevity applications and risks of the triple blend; provides balanced perspective on GH/IGF-1 optimization, including the importance of avoiding supraphysiological levels)
Holst B, Culler MD, Schwartz TW. Common structural basis for constitutive activity of the ghrelin receptor family. Journal of Biological Chemistry. 2003;278(42):41140-41147. (Key paper on GHSR-1a (ghrelin receptor) structure and pharmacology, covering: receptor structure, constitutive activity, ligand binding, signaling pathways, and the molecular basis of GHSR agonist selectivity (including ipamorelin's selective binding profile vs GHRP-2/GHRP-6); provides the molecular pharmacology context for understanding why ipamorelin is more GH-selective than GHRP-2, and how two GHRPs with different structures may interact with the receptor; relevant to the dual-GHRP component of the triple blend and the potential for additive/synergistic receptor activation)
Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1990;323(1):1-6. (LANDMARK study that popularized GH replacement for aging: 6 months of GH replacement in men aged 61-81 produced 8.8% increase in lean body mass, 14.4% decrease in adipose tissue, 1.6% increase in lumbar spine bone density, 7.1% increase in skin thickness, and improved quality of life; described changes as "equivalent in magnitude to the changes incurred during 10 to 20 years of aging"; this study is the foundation for the concept of GH replacement for somatopause and anti-aging, and provides context for the expected body composition effects of GH/IGF-1 elevation from the triple blend; also discusses side effects [edema, arthralgias, carpal tunnel] that are important safety considerations, particularly with more robust GH release from the triple blend)
Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interaction with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism. 2001;86(3):1169-1174. (Clinical study comparing ghrelin, hexarelin (a GHRP), and GHRH in humans, covering: GH-releasing potency of each, the synergistic interaction between GHS (ghrelin/hexarelin) and GHRH (greater GH release with combination vs either alone), hypothalamic vs pituitary mechanisms, effects on other hormones (prolactin, ACTH/cortisol, insulin, glucose), and safety; provides clinical evidence for the GHS + GHRH synergy that underlies the GHRP-2/Ipamorelin + CJC-1295 triple blend; also discusses differential effects of various GHS on prolactin/ACTH (relevant to ipamorelin's selectivity vs GHRP-2's moderate effects, and the balanced profile of the triple blend))
Melmed S. Pathophysiology of pituitary growth hormone hypersecretion and clinical consequences. Endocrinology and Metabolism Clinics of North America. 2020;49(3):373-387. (Comprehensive review of GH physiology, pathophysiology, and clinical consequences, covering: normal GH secretion (pulsatile, hypothalamic regulation by GHRH/somatostatin, ghrelin), GH signaling (JAK2/STAT5, IGF-1), GH actions (anabolic, lipolytic, metabolic, cardiovascular, bone, brain), GH deficiency (causes, symptoms, diagnosis, replacement therapy), GH excess (acromegaly — causes, symptoms, treatment), the relationship between GH/IGF-1 and aging/metabolic syndrome/cancer, and the risks and benefits of GH therapy; provides the comprehensive physiological and clinical context for the triple blend; relevant to understanding both the benefits and risks of GH/IGF-1 elevation, particularly with the more robust release from the triple blend, and the importance of IGF-1 monitoring to avoid supraphysiological levels)
CJC-1295: ~6-8 days (No DAC) or ~8-12 days (with DAC); Ipamorelin: ~90-120 minutes; GHRP-2: ~30-60 minutes; Combination: sustained GHRH background + medium + acute GH pulses (multi-phase release)
Typical Research Dose
Classic protocol: CJC-1295 100-200mcg + Ipamorelin 100-300mcg + GHRP-2 100-200mcg per injection, 1-3x daily (typically before bed and/or post-workout); CJC-1295 with DAC: 1-2mg once weekly + Ipamorelin 100-300mcg + GHRP-2 100-200mcg 1-3x daily; 9mg vial allows flexible dosing; SC injection; NOT orally active; 3-6 month cycles with IGF-1 monitoring; start low, titrate; monitor for supraphysiological IGF-1
Administration
Subcutaneous (SC) injection (abdomen, thigh — rotate sites); 29-31G insulin syringe; injection volume 0.1-0.5mL; typically dosed 1-3x daily (CJC-1295 No DAC) or 1-2x weekly (CJC-1295 with DAC); best timing: before bed (to augment natural deep-sleep GH pulse — minimal appetite means less nighttime hunger) and/or post-workout; NOT orally active; best on empty stomach (2-3 hours after last meal) for maximum GH release; avoid alcohol and high-carb/high-fat meals within 1-2 hours of dosing
Storage (Lyophilized)
-20°C, protect from light/moisture; stable 24+ months
Storage (Reconstituted)
2-8°C, protect from light; stable 14-30 days; do NOT freeze
Common Side Effects
Injection site reactions (pain, redness, swelling ~5-15%), transient flushing/warmth (GHRPs — usually mild), water retention/edema (GH effect — especially at higher doses), numbness/tingling (paresthesia, carpal tunnel-like — GH effect), headache, fatigue, insomnia or vivid dreams (if dosed too late; most users report improved sleep), mild nausea (rare), joint pain (arthralgia — GH effect), increased sweating, mild glucose elevation (GH anti-insulin effect — monitor), sleepiness (GHRPs — some users report mild drowsiness); BALANCED due to Ipamorelin: minimal appetite increase (unlike GHRP-6), minimal-moderate prolactin elevation (Ipamorelin minimal + GHRP-2 moderate = balanced), minimal-moderate ACTH/cortisol elevation (Ipamorelin minimal + GHRP-2 moderate = balanced) — better tolerated than CJC+GHRP-2 alone at equivalent total GHRP dose
Serious Risks
Insulin resistance/glucose intolerance (GH anti-insulin effect — monitor), acromegaly-like features (with long-term supraphysiological GH — avoid supraphysiological doses; triple blend's robust GH release increases this risk if not monitored), carpal tunnel syndrome (GH-induced fluid retention), edema/hypertension (fluid retention), gallbladder disease (with rapid weight changes), pituitary suppression (theoretical with long-term use), cancer risk (high IGF-1 is mitogenic/anti-apoptotic — theoretical increased risk; avoid in active cancer; monitor in high-risk; triple blend's robust GH/IGF-1 elevation makes careful monitoring essential), hyperprolactinemia (GHRP-2 component — more than Ipamorelin alone; monitor if concerned), allergic reaction (rare), hypoglycemia (rare)
Contraindications
Active malignancy/cancer (theoretical — GH/IGF-1 mitogenic; avoid), pituitary tumors (prolactinoma, acromegaly — GH/IGF-1 may stimulate), diabetic retinopathy (rapid GH/IGF-1 changes may worsen), severe respiratory disease/sleep apnea (GH fluid retention may worsen), pregnancy/lactation, children (unless diagnosed GH deficiency under medical supervision), known allergy to CJC-1295/Ipamorelin/GHRP-2 or excipients; caution in: diabetes/prediabetes (monitor glucose — triple blend's robust GH release may worsen insulin resistance), carpal tunnel, edema/hypertension, liver/kidney disease, history of cancer (monitor IGF-1/PSA/mammograms), elderly (frailty, dose adjustment), BPH in men (monitor PSA), prolactin-sensitive conditions (GHRP-2 component may increase prolactin — monitor)
Monitoring
IGF-1 (PRIMARY BIOMARKER — measure after 4-6 weeks, target upper-normal for age ~200-350 ng/mL adults; ESSENTIAL for triple blend due to robust GH release — avoid supraphysiological), fasting glucose + HbA1c (monitor insulin resistance), lipid panel, liver/kidney function, CBC, prolactin (GHRP-2 component — monitor if concerned), cortisol/ACTH (GHRP-2 component — monitor if concerned), PSA in men (monitor prostate), body composition (DXA/bioimpedance), bone density (if long-term, 12-24 months), symptoms (edema, arthralgia, carpal tunnel, sleep changes, mood)
Quality Control
Identity (mass spec for each of 3 peptides), purity (HPLC ≥98% each), endotoxin (LAL <0.5 EU/mg), sterility, appearance, peptide content/ratio verification (CJC-1295:Ipamorelin:GHRP-2 ratio confirmed), DAC verification (if CJC-1295 with DAC); COA available
Research Status
Investigational triple blend; CJC-1295 (modified GRF 1-29) researched for GH deficiency, aging, body composition; Ipamorelin extensively researched (first selective GHS, Raun et al. 1998); GHRP-2 extensively researched (potent GHRP); dual GHRP combinations (Ipamorelin + GHRP-2) are an active area of research (optimal ratios, dosing, pharmacokinetics, safety not fully established); triple blend (GHRH + dual GHRP) is a "maximalist" approach to GH release; NOT FDA-approved; for laboratory/investigational use only; WADA-prohibited for athletic use (doping)
What is the CJC-1295 + Ipamorelin + GHRP-2 triple blend (9mg), why combine two GHRPs (Ipamorelin + GHRP-2), how is it different from single-GHRP combinations (CJC+GHRP-2, CJC+Ipamorelin, CJC+GHRP-6), how do the three peptides work synergistically to release growth hormone, what effects can be expected (muscle, fat, recovery, sleep, anti-aging), how do I dose and reconstitute it, what are the side effects and safety considerations (especially given the robust GH release), and who is this blend best suited for?
The CJC-1295 + Ipamorelin + GHRP-2 triple blend (9mg total per vial) is a "maximalist" growth hormone-releasing peptide combination that brings together THREE peptides: (1) CJC-1295 — a long-acting analog of growth hormone-releasing hormone (GHRH), also known as modified GRF 1-29 (D-Ala², Glu⁸, Ala¹⁵, Leu²⁷ substitutions to resist DPP-IV degradation); it binds to GHRH receptors (GHRHR, Gs-GPCR) on pituitary somatotrophs, stimulating GH SYNTHESIS (via cAMP/PKA/CREB → GH gene transcription) and priming the somatotroph for GH release; it has a long half-life (~6-12 days) that provides a sustained GHRH "background" signal; (2) Ipamorelin — a highly selective pentapeptide growth hormone secretagogue (sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib=2-aminoisobutyric acid, D-2-Nal=D-2-naphthylalanine), developed through SAR studies to be the MOST GH-SELECTIVE secretagogue (Raun et al., European Journal of Endocrinology, 1998 — "Ipamorelin, the first selective growth hormone secretagogue"); it binds to GHSR-1a (ghrelin receptor, Gq/11-GPCR) on pituitary somatotrophs and hypothalamic neurons, stimulating acute GH RELEASE (via PLC/IP3/DAG → intracellular calcium release → GH exocytosis) AND inhibiting somatostatin at the hypothalamus; it has MINIMAL effects on prolactin, ACTH/cortisol, and appetite (unlike GHRP-6/GHRP-2); it has a longer half-life (~90-120 min) than GHRP-2 due to the Aib substitution; (3) GHRP-2 — a potent hexapeptide growth hormone-releasing peptide (sequence: D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2); it also binds to GHSR-1a on pituitary somatotrophs and hypothalamic neurons, stimulating potent, reliable acute GH RELEASE via the same PLC/IP3/calcium pathway; it has minimal appetite stimulation (unlike GHRP-6) but moderate prolactin/ACTH effects (more than Ipamorelin); it has a shorter half-life (~30-60 min) that produces sharp, discrete GH pulses. The blend typically contains ~3mg CJC-1295 + ~3mg Ipamorelin + ~3mg GHRP-2 (1:1:1 ratio, though verify exact ratio from supplier COA). WHY COMBINE TWO GHRPs (Ipamorelin + GHRP-2)? This is the distinctive feature of this triple blend. The rationale includes: (a) ADDITIVE OR SYNERGISTIC GHSR-1a RECEPTOR ACTIVATION: Although both Ipamorelin and GHRP-2 bind to the GHSR-1a (ghrelin) receptor, they have different chemical structures, binding kinetics, and conformational effects on the receptor. Ipamorelin (pentapeptide with Aib and D-2-Nal) may bind with slightly different affinity and induce a slightly different receptor conformation than GHRP-2 (hexapeptide with D-Ala and D-β-Nal). This could lead to biased signaling or more sustained receptor activation (different dissociation rates). Some researchers believe combining two GHRPs with different pharmacokinetic profiles can produce more robust and consistent GH release than either GHRP alone; (b) COMPLEMENTARY PHARMACOKINETICS: Ipamorelin has a longer half-life (~90-120 min) than GHRP-2 (~30-60 min). The combination may provide both an initial sharp GH pulse (from GHRP-2's rapid onset and short half-life) and a more sustained GH-releasing effect (from Ipamorelin's longer half-life), potentially producing a broader and more robust GH release profile — a "multi-phase" GH release; (c) BALANCED SIDE EFFECT PROFILE: GHRP-2 is potent but has moderate effects on prolactin and ACTH/cortisol. Ipamorelin is the most selective GHRP with minimal prolactin/ACTH/appetite effects. By combining the two, the blend may achieve the potent GH release of GHRP-2 while the Ipamorelin component helps "dilute" or balance the off-target effects of GHRP-2 (since a portion of the total GHRP dose comes from the more selective Ipamorelin, the effective dose of GHRP-2 is lower than it would be in a CJC+GHRP-2-only blend with the same total GHRP content). This could result in a better tolerated blend with fewer prolactin/cortisol-related side effects than a CJC+GHRP-2 blend of equivalent total GHRP dose; (d) MORE ROBUST SOMATOSTATIN INHIBITION: Both GHRPs inhibit somatostatin (the primary inhibitor of GH) at the hypothalamic level. Using two GHRPs may produce greater net somatostatin suppression than one GHRP alone, further enhancing the effectiveness of CJC-1295 (which is suppressed by somatostatin when used alone); (e) MORE ROBUST HYPOTHALAMIC GHRH STIMULATION: Both GHRPs stimulate hypothalamic GHRH release, complementing exogenous CJC-1295 and further enhancing the GHRH signal reaching the pituitary; (f) INDIVIDUAL VARIABILITY: Different individuals may respond differently to different GHRPs due to genetic variations in GHSR-1a receptor expression, receptor polymorphisms, metabolic differences, etc. Combining two GHRPs increases the likelihood that at least one will be highly effective for a given individual. It is important to note that dual GHRP combinations are still an active area of research, and the optimal ratio, dosing, and long-term safety are not yet fully established. DIFFERENCE FROM SINGLE-GHRP COMBINATIONS: - CJC-1295 + GHRP-6: Original/classic; GHRP-6 = potent appetite stimulant + more prolactin/ACTH; BEST for bulking/poor appetite/wasting; LESS suitable for cutting. - CJC-1295 + GHRP-2: Potent, reliable GH release; minimal appetite; moderate prolactin/ACTH; GOOD for general use/cutting. - CJC-1295 + Ipamorelin: MOST SELECTIVE/GENTLEST; minimal appetite + minimal prolactin + minimal ACTH + similar GH potency; BEST for sensitive individuals, older adults, beginners, long-term use, cutting. - CJC-1295 + Ipamorelin + GHRP-2 (THIS TRIPLE BLEND): "MAXIMALIST" approach; combines GHRH (CJC-1295) with TWO complementary GHRPs (Ipamorelin for selectivity/gentleness + GHRP-2 for potency); potentially MORE ROBUST GH release than single-GHRP combinations due to additive GHSR activation, complementary pharmacokinetics (multi-phase release), more robust somatostatin inhibition, and more robust GHRH stimulation; BALANCED side effects (Ipamorelin offsets GHRP-2's prolactin/ACTH effects); minimal appetite (both GHRPs have minimal appetite, unlike GHRP-6) — suitable for cutting and clean bulking; BEST for those who want maximum GH output while maintaining a reasonable side effect profile, those who have tried single-GHRP combinations and want more robust release, and those with lower GH responsiveness. THE TRIPLE GHRH/GHRP SYNERGY (how they work together): The combination produces SYNERGISTIC (2-10x greater, and potentially more with dual GHRPs) growth hormone release through: (a) PITUITARY-LEVEL SYNERGY: CJC-1295 activates the Gs/cAMP/PKA pathway (increasing GH synthesis, "priming" the somatotroph, sensitizing calcium channels), while both Ipamorelin and GHRP-2 activate the Gq/PLC/IP3/calcium pathway ("triggering" massive GH exocytosis by releasing stored intracellular calcium). The two GHRPs may have additive effects on GHSR-1a activation due to their different binding profiles; (b) HYPOTHALAMIC-LEVEL SYNERGY: Both GHRPs stimulate hypothalamic GHRH release (complementing exogenous CJC-1295) AND inhibit hypothalamic somatostatin release (removing the "brake" on GH — somatostatin suppresses CJC-1295's effects when CJC is used alone). Using two GHRPs may produce more robust somatostatin inhibition and GHRH stimulation than one GHRP alone; (c) MULTI-PHASE PHYSIOLOGICAL PULSATILE RELEASE: CJC-1295 (long half-life, ~6-12 days) provides a sustained GHRH "background" signal; Ipamorelin (medium half-life, ~90-120 min) provides sustained GH-releasing activity; GHRP-2 (short half-life, ~30-60 min) produces sharp acute GH pulses. This triple combination of long + medium + short half-life peptides produces a multi-phase GH release profile that may generate more total GH output than any single or dual combination, while still mimicking the physiological pulsatile pattern (largest pulses during deep sleep); (d) IGF-1 ELEVATION: The greater GH release translates to greater hepatic IGF-1 (insulin-like growth factor-1, somatomedin C) production — IGF-1 is the primary downstream mediator of GH's effects, and the triple blend may elevate IGF-1 by 30-100%+ (potentially more than single-GHRP combinations due to more robust GH release); IGF-1 is the primary biomarker for monitoring (GH is pulsatile and random levels are meaningless, while IGF-1 is stable and reflects integrated GH secretion); (e) BALANCED SIDE EFFECTS: Ipamorelin's minimal prolactin/ACTH/appetite effects help balance GHRP-2's moderate effects on these hormones, making the triple blend potentially better tolerated than a CJC+GHRP-2-only blend at equivalent total GHRP dose. EXPECTED EFFECTS (with consistent use over 3-6 months, monitored by IGF-1 to keep levels physiological, NOT supraphysiological): (1) ROBUST GH/IGF-1 ELEVATION: - Potentially more robust GH release and IGF-1 elevation than single-GHRP combinations (due to dual GHRP additive effects, multi-phase release, more robust somatostatin inhibition) - IGF-1 elevation of 30-100%+ (potentially more, depending on dose and individual response) - MUST be monitored carefully to avoid supraphysiological IGF-1 (which increases side effect risk) (2) BODY COMPOSITION/MUSCLE/FAT: - Increased lean body mass (5-10% over 6-12 months in GH-deficient individuals; more modest in healthy adults; potentially enhanced by more robust GH/IGF-1) - Reduced body fat (10-15% over 6-12 months), particularly visceral/abdominal fat - Improved body composition (higher lean %, lower fat %) - GH/IGF-1 stimulate muscle protein synthesis (mTOR pathway, satellite cell activation) + inhibit muscle protein breakdown (ubiquitin-proteasome, myostatin reduction) - GH is a potent lipolytic hormone (hormone-sensitive lipase activation + lipoprotein lipase inhibition) - Effects significantly enhanced with resistance training + adequate protein (1.6-2.2g/kg/day) - MINIMAL APPETITE stimulation (both Ipamorelin and GHRP-2 have minimal appetite effects, unlike GHRP-6) → suitable for both cutting (caloric deficit) and "clean bulking" (controlled caloric surplus without excessive fat gain) (3) RECOVERY/TISSUE REPAIR: - Faster post-workout recovery, reduced DOMS (delayed onset muscle soreness) - Improved tendon/ligament healing (collagen synthesis, fibroblast proliferation, angiogenesis) - Potential cartilage support (chondrocyte proliferation, type II collagen/aggrecan synthesis) - Improved bone healing/density (12-24 months) - Enhanced wound/skin healing - Potentially enhanced recovery effects due to more robust GH/IGF-1 elevation (4) SLEEP QUALITY: - Deeper, more restorative sleep, fewer nighttime awakenings - Better sleep architecture (more slow-wave/deep sleep — when GH is naturally released) - Reduced daytime fatigue - Often one of the first noticeable effects (1-2 weeks) - MINIMAL APPETITE means less likely to cause nighttime hunger if dosed before bed (unlike GHRP-6) → bedtime dosing well-tolerated (5) COGNITION/MOOD/QUALITY OF LIFE: - Improved memory, attention, executive function (GH/IGF-1 receptors in hippocampus/cortex, neurogenesis, synaptic plasticity) - Improved mood/motivation, reduced anxiety/depression symptoms (neurogenesis + neurotransmitter modulation + anti-inflammatory) - Increased energy/vitality - Improved overall quality of life - BALANCED ACTH/cortisol effects (Ipamorelin's minimal cortisol offsets GHRP-2's moderate effect) → advantageous for mood/cognition (elevated cortisol can impair cognition and cause anxiety) - BALANCED prolactin effects (Ipamorelin's minimal prolactin offsets GHRP-2's moderate effect) → advantageous for mood/sexual function (elevated prolactin can cause mood changes and sexual dysfunction) (6) ANTI-AGING/SOMATOPAUSE: - Counteracts age-related GH decline (somatopause — GH declines ~14%/decade after age 30) - Improved skin thickness/elasticity (collagen/elastin synthesis, reduced wrinkles) - Improved bone density (12-24 months) - Improved body composition, energy, vitality - IMPORTANT CAVEAT: The relationship between GH/IGF-1 and longevity is complex — reduced GH/IGF-1 signaling in model organisms (GHRKO mice, Ames dwarf) is associated with INCREASED lifespan, and high IGF-1 may increase cancer risk; the optimal range is physiological/upper-normal (not supraphysiological), with appropriate monitoring. This is ESPECIALLY important for the triple blend due to its potentially more robust GH/IGF-1 elevation — careful IGF-1 monitoring is essential to avoid supraphysiological levels. RECONSTITUTION: Add bacteriostatic water (preferred for multi-dose) to desired concentration — common: +1mL → 9mg/mL (1mg=0.11mL, 0.5mg=0.056mL, 0.3mg=0.033mL, 0.1mg=0.011mL); +2mL → 4.5mg/mL (1mg=0.22mL, 0.5mg=0.11mL); +3mL → 3mg/mL (1mg=0.33mL, 0.5mg=0.17mL); +5mL → 1.8mg/mL (1mg=0.56mL, 0.5mg=0.28mL); +9mL → 1mg/mL (1mg=1.0mL, 0.5mg=0.5mL). Inject water SLOWLY against vial side wall (NOT directly onto powder — causes foaming/denaturation); gently swirl (do NOT shake) until clear; store reconstituted at 2-8°C, protect from light, stable 14-30 days, do NOT freeze. DOSING (research, classic protocol): The classic CJC-1295 + Ipamorelin + GHRP-2 protocol: (a) CJC-1295 (No DAC): 100-200mcg per injection + Ipamorelin: 100-300mcg per injection + GHRP-2: 100-200mcg per injection, mixed in the same syringe and injected together; (b) Frequency: 1-3x daily — most commonly: (i) before bed (30-60 min before sleep — to augment the natural deep-sleep GH pulse; minimal appetite means less nighttime hunger); (ii) post-workout (immediately after resistance training — to augment exercise-induced GH release and support recovery); (iii) some users add a third dose in the morning (fasted); (c) CJC-1295 WITH DAC: 1-2mg once weekly (instead of daily CJC-1295), combined with Ipamorelin 100-300mcg + GHRP-2 100-200mcg 1-3x daily (the DAC form has a long half-life [~8-12 days] so it doesn't need daily dosing); (d) With the 9mg blend vial (~3mg each peptide at 1:1:1): to inject 100mcg CJC + 100mcg Ipamorelin + 100mcg GHRP-2 = 300mcg (0.3mg) total blend (at 9mg/mL = 0.033mL; at 4.5mg/mL = 0.067mL; at 3mg/mL = 0.1mL; at 1mg/mL = 0.3mL); to inject 150mcg CJC + 200mcg Ipamorelin + 150mcg GHRP-2 = 500mcg (0.5mg) total (at 9mg/mL = 0.056mL; at 3mg/mL = 0.17mL); (e) Cycle length: 3-6 months, then 1-2 month break (to allow pituitary recovery, though pulsatile endogenous release is less suppressive than exogenous HGH); (f) IGF-1 MONITORING IS ESSENTIAL — ESPECIALLY FOR THIS TRIPLE BLEND: measure serum IGF-1 after 4-6 weeks of dosing, adjust dose to keep IGF-1 in the upper-normal range for age (~200-350 ng/mL adults) — NOT supraphysiological. Because the triple blend may produce more robust GH/IGF-1 elevation than single-GHRP combinations, careful monitoring is even more important to avoid supraphysiological levels (which increase side effect risk: insulin resistance, edema, carpal tunnel, acromegaly-like features with long-term use, theoretical cancer risk). IGF-1 is the primary biomarker because GH is pulsatile and difficult to measure accurately; (g) Start LOW (e.g., 100mcg CJC + 100mcg Ipamorelin + 100mcg GHRP-2 once daily before bed) and titrate up gradually based on IGF-1 response and side effects; (h) These are research doses based on common protocols, NOT medical advice; individual response varies; verify exact CJC-1295:Ipamorelin:GHRP-2 ratio from COA for accurate dosing; verify whether CJC-1295 has DAC or not (affects dosing frequency). ADMINISTRATION: Subcutaneous (SC) injection with 29-31G insulin syringe; rotate injection sites (abdomen [preferred — most consistent absorption], front of thighs, upper arms); injection volume 0.1-0.5mL; the three peptides can be mixed in the same syringe (use pre-blended vial); do NOT inject intravenously or intramuscularly (SC is standard); NOT orally active; for maximum GH release: best on an empty stomach (2-3 hours after last meal), avoid alcohol, avoid high-carb/high-fat meals within 1-2 hours of dosing; for bedtime dosing: the blend's minimal appetite (both Ipamorelin and GHRP-2 have minimal appetite effects) makes it less likely to cause nighttime hunger (unlike GHRP-6), so bedtime dosing is well-tolerated. SIDE EFFECTS: The triple blend has a BALANCED side effect profile due to Ipamorelin's selectivity helping offset GHRP-2's off-target effects, but the potentially more robust GH release means GH-related side effects may be more pronounced if not carefully monitored (IGF-1). COMMON (mild, usually transient, dose-dependent): - Injection site reactions (pain, redness, swelling, itching ~5-15%) - Transient flushing/warmth (GHRPs — usually mild, lasts 10-30 min) - Water retention/edema (GH effect — especially at higher doses or rapid escalation; usually mild and transient; may be more pronounced with the triple blend's robust GH release if not monitored) - Numbness/tingling (paresthesia — fingers, hands, feet; GH-induced fluid retention can compress nerves; carpal tunnel-like; usually transient, reduce dose if persistent) - Headache (usually mild, transient) - Fatigue or lethargy (especially at initiation — the body adjusts) - Insomnia or vivid dreams (if dosed too late or too high in some individuals; most users report IMPROVED sleep; the blend's minimal appetite means less likely to cause nighttime hunger unlike GHRP-6) - Mild nausea (rare, usually at high doses) - Joint pain (arthralgia — GH effect, especially at higher doses; usually mild) - Increased sweating (GH increases metabolic rate/thermogenesis) - Mild glucose elevation (GH anti-insulin effect — monitor, especially in diabetics/prediabetics; usually resolves with dose adjustment; may be more pronounced with the triple blend's robust GH release if not monitored) - Sleepiness/drowsiness (GHRPs — some users report mild drowsiness after injection, especially at higher doses) BALANCED OFF-TARGET EFFECTS (due to Ipamorelin + GHRP-2 combination): - MINIMAL APPETITE INCREASE (both Ipamorelin and GHRP-2 have minimal appetite effects, unlike GHRP-6 which is a potent appetite stimulant — the triple blend is suitable for cutting and clean bulking) - MINIMAL TO MODERATE PROLACTIN ELEVATION (Ipamorelin has minimal prolactin effect, GHRP-2 has moderate effect — the combination is balanced, potentially less than CJC+GHRP-2 alone at equivalent total GHRP dose; usually mild and transient; monitor if concerned) - MINIMAL TO MODERATE ACTH/CORTISOL ELEVATION (Ipamorelin has minimal ACTH/cortisol effect, GHRP-2 has moderate effect — the combination is balanced, potentially less than CJC+GHRP-2 alone; usually mild and transient; monitor if concerned) LESS COMMON / SERIOUS (seek medical attention if persistent/severe): - Insulin resistance / glucose intolerance / type 2 diabetes (GH anti-insulin effect — monitor fasting glucose and HbA1c; risk increases with supraphysiological doses; the triple blend's robust GH release may increase this risk if IGF-1 is not carefully monitored; usually reversible with dose reduction/discontinuation) - Acromegaly-like features (with LONG-TERM supraphysiological GH: enlarged hands/feet, jaw prognathism, facial coarsening — requires years of high-dose use; avoid supraphysiological IGF-1 levels; the triple blend's robust GH release makes careful monitoring even more important) - Carpal tunnel syndrome (GH-induced fluid retention compressing median nerve — numbness/tingling/weakness in hands; reduce dose, may require medical treatment) - Edema / hypertension (fluid retention can increase blood pressure — monitor BP, especially in hypertensive individuals; reduce dose/sodium intake) - Gallbladder disease / gallstones (with rapid weight changes — monitor, especially with history of gallstones) - Pituitary suppression (theoretical with long-term use — though pulsatile endogenous GH release is less suppressive than continuous exogenous HGH; take breaks between cycles; monitor) - Cancer risk (theoretical — IGF-1 is mitogenic [stimulates cell proliferation] and anti-apoptotic [inhibits cell death]; high IGF-1 may increase risk of prostate, breast, colorectal cancers — though evidence is complex and confounded; AVOID in active cancer; monitor in high-risk individuals [family history, PSA in men, mammograms]; keep IGF-1 physiological, not supraphysiological — the triple blend's robust GH/IGF-1 elevation makes careful monitoring essential) - Hyperprolactinemia (GHRP-2 component — more than Ipamorelin alone; persistent high prolactin can cause galactorrhea, menstrual irregularities, sexual dysfunction; monitor if concerned; the Ipamorelin component helps balance this) - Allergic reaction (rash, hives, itching; severe anaphylaxis very rare) - Hypoglycemia (rare — GHRPs may transiently affect insulin/glucose; more common in diabetics on medication; monitor) SAFETY CONSIDERATIONS / CONTRAINDICATIONS: - ABSOLUTE CONTRAINDICATIONS: active malignancy/cancer (theoretical GH/IGF-1 mitogenic effects could stimulate tumor growth — AVOID; the triple blend's robust GH/IGF-1 elevation makes this even more important), pituitary tumors (especially prolactinoma, GH-secreting adenoma/acromegaly — GH/IGF-1 may stimulate tumor growth; GHRP-2 component may also affect prolactin), diabetic retinopathy (rapid GH/IGF-1 changes may worsen retinal condition — get eye exam before use), severe respiratory disease/sleep apnea (GH fluid retention may worsen airway obstruction — caution), pregnancy/lactation (GH/IGF-1 effects on fetus/infant not well studied — AVOID), children (unless for diagnosed GH deficiency under pediatric endocrinologist supervision — improper use can close growth plates prematurely), known hypersensitivity to CJC-1295, Ipamorelin, GHRP-2, or any excipients - CAUTION / MONITORING: diabetes or prediabetes (monitor fasting glucose, HbA1c, insulin sensitivity — GH can worsen insulin resistance; the triple blend's robust GH release may increase this risk; may need medication adjustment), carpal tunnel syndrome or peripheral neuropathy (GH fluid retention may worsen), edema or hypertension (monitor BP, fluid retention), liver or kidney disease (peptides metabolized/cleared by kidneys; adjust dose in severe impairment), history of cancer (monitor IGF-1, PSA [men], mammograms [women], use with caution; the triple blend's robust GH/IGF-1 elevation makes careful monitoring essential), elderly (frailty, sarcopenia — may benefit but start at lower doses, monitor closely; Ipamorelin's gentleness helps balance GHRP-2's potency), benign prostatic hyperplasia (BPH) in men (monitor PSA and urinary symptoms — IGF-1 may affect prostate), prolactin-sensitive conditions (GHRP-2 component may increase prolactin — monitor; Ipamorelin helps balance), use of corticosteroids or immunosuppressants (cortisol counteracts GH's anabolic effects — high steroid doses may blunt GH response), thyroid hormone (GH affects thyroid hormone metabolism — monitor TSH/free T4, may need adjustment), estrogens/testosterone (sex hormones interact with GH/IGF-1 axis — monitor), anticoagulants (no major interaction, but monitor), other GH-releasing peptides or HGH (do NOT combine multiple GH secretagogues or HGH without medical supervision — risk of excessive GH/IGF-1; the triple blend already contains two GHRPs + GHRH analog, so adding more would be excessive) - DRUG INTERACTIONS: insulin/oral hypoglycemics (GH anti-insulin effect may increase glucose — monitor, may need dose adjustment), corticosteroids (cortisol counteracts GH's anabolic effects), thyroid hormone (GH affects thyroid metabolism), estrogens/testosterone (interact with GH/IGF-1 axis), alcohol (suppresses GH release — avoid around dosing), high-carb/high-fat meals (blunt GH release — avoid within 1-2 hours of dosing for maximum GH effect) - IMPORTANT: This is a RESEARCH PEPTIDE BLEND for LABORATORY/INVESTIGATIONAL USE ONLY — NOT for human consumption or therapeutic use; NOT FDA-approved as a combination (CJC-1295 is investigational, Ipamorelin and GHRP-2 are research-grade; dual GHRP combinations are an active area of research with limited long-term human safety data); source from reputable suppliers with COA (identity [mass spec for EACH of the 3 peptides], purity ≥98% [HPLC], endotoxin <0.5 EU/mg [LAL], sterility, peptide content/RATIO verification [CJC:Ipamorelin:GHRP-2 ratio confirmed], DAC verification); use proper sterile technique; WADA-PROHIBITED for athletic use (GH-releasing peptides are on the WADA prohibited list as doping agents — do not use if competing in sanctioned sports); if any PERSISTENT or SEVERE side effects occur (severe edema, severe headache/visual changes [possible pituitary issue], severe joint pain, signs of carpal tunnel, persistent numbness/tingling, signs of diabetes (excessive thirst/urination/fatigue), signs of allergic reaction, mood changes, signs of high prolactin (galactorrhea, menstrual irregularities, sexual dysfunction), or other concerning symptoms), discontinue and SEEK MEDICAL ATTENTION. This information is for educational/laboratory use only and does NOT constitute medical advice. WHO IS THIS BLEND BEST SUITED FOR: The CJC-1295 + Ipamorelin + GHRP-2 triple blend is BEST suited for: (1) THOSE WHO WANT MAXIMUM/ROBUST GH RELEASE — individuals who want the most powerful GH/IGF-1 elevation among GHRH/GHRP combinations, due to the dual GHRP (Ipamorelin + GHRP-2) additive/synergistic effects, multi-phase release (long + medium + short half-life), and more robust somatostatin inhibition/GHRH stimulation; (2) THOSE WHO HAVE TRIED SINGLE-GHRP COMBINATIONS AND WANT MORE — individuals who have used CJC+GHRP-2, CJC+Ipamorelin, or CJC+GHRP-6 and feel they need more robust GH release or higher IGF-1 elevation (while monitoring carefully to avoid supraphysiological levels); (3) THOSE WITH LOWER GH RESPONSIVENESS — individuals who may be less responsive to single-GHRP combinations (due to genetics, age, body composition, or other factors) and may benefit from the stronger stimulation of dual GHRPs + GHRH analog; (4) THOSE WHO WANT A BALANCED SIDE EFFECT PROFILE WITH POTENT GH RELEASE — individuals who want the potent GH release of GHRP-2 but are concerned about its prolactin/ACTH effects; the addition of Ipamorelin (the most selective GHRP) helps balance these off-target effects, making the triple blend potentially better tolerated than CJC+GHRP-2 alone at equivalent total GHRP dose; (5) THOSE IN CUTTING/FAT LOSS PHASES — the triple blend has MINIMAL appetite stimulation (both Ipamorelin and GHRP-2 have minimal appetite effects, unlike GHRP-6), making it suitable for fat loss phases where maintaining a caloric deficit is important; (6) THOSE DOING "CLEAN BULKING" — individuals who want to gain muscle with minimal fat gain; the blend's minimal appetite stimulation makes it easier to control caloric intake and avoid excessive fat gain during a bulking phase (unlike GHRP-6 which can cause overeating), while the robust GH/IGF-1 elevation supports muscle growth; (7) EXPERIENCED USERS WHO UNDERSTAND THE IMPORTANCE OF IGF-1 MONITORING — because the triple blend may produce more robust GH/IGF-1 elevation than single-GHRP combinations, it is particularly important that users understand the need for careful IGF-1 monitoring to keep levels physiological (upper-normal), NOT supraphysiological; beginners should start with single-GHRP combinations (like CJC+Ipamorelin) before considering the triple blend. The CJC-1295 + Ipamorelin + GHRP-2 triple blend is LESS suited for: (1) BEGINNERS NEW TO GH-RELEASING PEPTIDES — those who are new to GHRH/GHRP peptides should start with a simpler, gentler single-GHRP combination (like CJC+Ipamorelin or CJC+GHRP-2) to assess individual response and tolerance before considering the more powerful triple blend; (2) THOSE WHO WANT MAXIMUM APPETITE STIMULATION FOR BULKING/WASTING — individuals who want/need increased appetite (for bulking or wasting conditions) may prefer GHRP-6-based blends (which are potent appetite stimulants); the triple blend has minimal appetite effects; (3) THOSE WHO ARE PRONE TO INSULIN RESISTANCE OR DIABETES — the triple blend's potentially more robust GH release may increase the risk of insulin resistance/glucose elevation (GH has anti-insulin effects); individuals with diabetes or prediabetes should use with extreme caution and careful monitoring, or consider a gentler single-GHRP combination; (4) THOSE WITH ACTIVE CANCER OR HIGH CANCER RISK — the triple blend's robust GH/IGF-1 elevation may theoretically increase cancer risk (IGF-1 is mitogenic/anti-apoptotic); individuals with active cancer should AVOID, and those with high cancer risk should use with extreme caution and careful monitoring, or consider a gentler single-GHRP combination; (5) THOSE WHO DO NOT PLAN TO MONITOR IGF-1 — because the triple blend may produce more robust GH/IGF-1 elevation, careful IGF-1 monitoring is ESSENTIAL to avoid supraphysiological levels; individuals who do not plan to monitor IGF-1 should use a gentler single-GHRP combination instead. In summary, the CJC-1295 + Ipamorelin + GHRP-2 triple blend is a "maximalist" GHRH/GHRP combination that brings together the sustained GHRH signal of CJC-1295 with two complementary GHRPs (Ipamorelin for selectivity/gentleness + GHRP-2 for potency), potentially producing more robust GH/IGF-1 elevation than single-GHRP combinations while maintaining a balanced side effect profile and minimal appetite stimulation. It is best suited for experienced users who want maximum GH output, understand the importance of IGF-1 monitoring, and want to maintain a reasonable side effect profile.
Every production batch undergoes rigorous quality control testing including HPLC purity analysis, mass spectrometry identity verification, endotoxin testing, and sterility verification.
